SMAC SMAC mimetics as potential cancer therapeutics in myeloid malignancies

摘要

Summary Evasion of apoptosis has been identified as one of the essential hallmarks of cancer. Inhibitor of apoptosis proteins ( IAP s) are implicated in a host of myeloid malignancies, providing the rationale for strategies aimed at neutralizing IAP s to lower the cancer cell apoptosis threshold. Modes of IAP antagonism may include down‐regulating IAP expression, up‐regulating endogenous pro‐apoptotic proteins, such as tumour necrosis factor‐α or Fas ligand, or directly antagonizing IAP activity against caspases. Direct targeting of IAP s using mimetics of the second mitochondria‐derived activator of caspase ( SMAC ) protein has shown therapeutic promise by sensitizing the effect of chemotherapy on malignant cells. In pre‐clinical studies, SMAC mimetics have demonstrated broad synergistic activity with a wide range of therapeutics, including cytotoxic chemotherapy, receptor tyrosine kinase inhibitors, agents targeting death receptors and alternative mechanisms of cell death, such as necroptosis or autophagy and immune check point blockade. SMAC mimetics represent a novel approach for further investigation in patients with high‐risk, chemo‐refractory blood cancers, as single agents or in thoughtfully selected combinations. In this review, we discuss the development and therapeutic rationale of small molecule SMAC mimetics, with an emphasis on agents in clinical development for myeloid malignancies.